Arch Biopartners Inc. (ARCH.V)
CAD 1.74
(-3.33%)
CAD 1.74
(-3.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.22 Million CAD | 198.71% |
| 2022 | 1.08 Million CAD | 21.14% |
| 2021 | 891.53 Thousand CAD | -80.3% |
| 2020 | 4.52 Million CAD | 92.96% |
| 2019 | 2.34 Million CAD | -25.96% |
| 2018 | 3.16 Million CAD | 68.45% |
| 2017 | 1.88 Million CAD | 91.8% |
| 2016 | 980.57 Thousand CAD | 5.84% |
| 2015 | 926.46 Thousand CAD | 148.97% |
| 2014 | 372.11 Thousand CAD | 113.4% |
| 2013 | 174.37 Thousand CAD | -44.56% |
| 2012 | 314.51 Thousand CAD | -26.57% |
| 2011 | 428.32 Thousand CAD | 215.09% |
| 2010 | 135.93 Thousand CAD | -25.22% |
| 2009 | 181.79 Thousand CAD | -83.1% |
| 2008 | 1.07 Million CAD | 34.91% |
| 2007 | 797.18 Thousand CAD | 38.75% |
| 2006 | 574.53 Thousand CAD | -32.49% |
| 2005 | 850.97 Thousand CAD | -61.19% |
| 2004 | 2.19 Million CAD | 58.91% |
| 2003 | 1.37 Million CAD | 516.35% |
| 2002 | 223.89 Thousand CAD | 13.53% |
| 2001 | 197.2 Thousand CAD | -86.62% |
| 2000 | 1.47 Million CAD | 79.84% |
| 1999 | 819.61 Thousand CAD | 24.09% |
| 1998 | 660.51 Thousand CAD | -46.45% |
| 1997 | 1.23 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1 Million CAD | 293.73% |
| 2024 Q3 | 389.82 Thousand CAD | -87.97% |
| 2024 Q2 | 3.23 Million CAD | 223.52% |
| 2023 Q3 | 474.3 Thousand CAD | -47.07% |
| 2023 FY | 5.24 Million CAD | 385.54% |
| 2023 Q4 | -516.88 Thousand CAD | -208.98% |
| 2023 Q2 | 896.03 Thousand CAD | -58.18% |
| 2023 Q1 | 2.14 Million CAD | 509.19% |
| 2022 Q1 | 108.91 Thousand CAD | 114.36% |
| 2022 Q3 | 196.94 Thousand CAD | -53.38% |
| 2022 FY | 1.08 Million CAD | 21.14% |
| 2022 Q4 | 351.74 Thousand CAD | 78.6% |
| 2022 Q2 | 422.43 Thousand CAD | 287.86% |
| 2021 Q2 | 1.03 Million CAD | -35.72% |
| 2021 FY | 891.53 Thousand CAD | -80.3% |
| 2021 Q4 | -758.29 Thousand CAD | 22.03% |
| 2021 Q3 | -972.51 Thousand CAD | -194.02% |
| 2021 Q1 | 1.6 Million CAD | 3.97% |
| 2020 Q3 | 2.17 Million CAD | 2642.96% |
| 2020 Q1 | 723.1 Thousand CAD | -27.68% |
| 2020 FY | 4.52 Million CAD | 92.96% |
| 2020 Q4 | 1.54 Million CAD | -28.87% |
| 2020 Q2 | 79.32 Thousand CAD | -89.03% |
| 2019 Q4 | 999.86 Thousand CAD | 1948.77% |
| 2019 Q3 | 48.8 Thousand CAD | -89.89% |
| 2019 FY | 2.34 Million CAD | -25.96% |
| 2019 Q2 | 482.71 Thousand CAD | -40.72% |
| 2019 Q1 | 814.23 Thousand CAD | 7.57% |
| 2018 Q2 | 599.65 Thousand CAD | 81.37% |
| 2018 Q1 | 330.61 Thousand CAD | 54.59% |
| 2018 FY | 3.16 Million CAD | 68.45% |
| 2018 Q4 | 756.91 Thousand CAD | -48.89% |
| 2018 Q3 | 1.48 Million CAD | 146.96% |
| 2017 Q4 | 213.87 Thousand CAD | -83.56% |
| 2017 Q3 | 1.3 Million CAD | 778.39% |
| 2017 FY | 1.88 Million CAD | 91.8% |
| 2017 Q1 | 230.16 Thousand CAD | -32.14% |
| 2017 Q2 | 148.05 Thousand CAD | -35.67% |
| 2016 Q3 | 177.54 Thousand CAD | -41.43% |
| 2016 FY | 980.57 Thousand CAD | 5.84% |
| 2016 Q1 | 160.73 Thousand CAD | -12.57% |
| 2016 Q2 | 303.11 Thousand CAD | 88.58% |
| 2016 Q4 | 339.17 Thousand CAD | 91.03% |
| 2015 FY | 926.46 Thousand CAD | 148.97% |
| 2015 Q2 | 187.97 Thousand CAD | -53.12% |
| 2015 Q3 | 153.66 Thousand CAD | -18.25% |
| 2015 Q4 | 183.84 Thousand CAD | 19.64% |
| 2015 Q1 | 400.98 Thousand CAD | 172.47% |
| 2014 Q1 | 49.43 Thousand CAD | -9.72% |
| 2014 Q2 | 53.84 Thousand CAD | 8.93% |
| 2014 Q4 | 147.16 Thousand CAD | 20.95% |
| 2014 FY | 372.11 Thousand CAD | 113.4% |
| 2014 Q3 | 121.67 Thousand CAD | 125.98% |
| 2013 Q2 | 76.49 Thousand CAD | 162.9% |
| 2013 Q4 | 54.75 Thousand CAD | 289.85% |
| 2013 Q1 | 29.09 Thousand CAD | -67.67% |
| 2013 Q3 | 14.04 Thousand CAD | -81.64% |
| 2013 FY | 174.37 Thousand CAD | -44.56% |
| 2012 Q2 | 56.68 Thousand CAD | -31.42% |
| 2012 Q4 | 89.98 Thousand CAD | 5.63% |
| 2012 FY | 314.51 Thousand CAD | -26.57% |
| 2012 Q3 | 85.18 Thousand CAD | 50.26% |
| 2012 Q1 | 82.66 Thousand CAD | -3.68% |
| 2011 Q4 | 85.82 Thousand CAD | -46.39% |
| 2011 FY | 428.32 Thousand CAD | 215.09% |
| 2011 Q3 | 160.08 Thousand CAD | 105.42% |
| 2011 Q2 | 77.93 Thousand CAD | -25.41% |
| 2011 Q1 | 104.48 Thousand CAD | 34.83% |
| 2010 Q2 | 24.03 Thousand CAD | -75.61% |
| 2010 FY | 135.93 Thousand CAD | -25.22% |
| 2010 Q4 | 77.49 Thousand CAD | 172.77% |
| 2010 Q3 | 28.41 Thousand CAD | 18.19% |
| 2010 Q1 | 98.57 Thousand CAD | 268.27% |
| 2009 Q4 | 26.76 Thousand CAD | -24.96% |
| 2009 FY | 181.79 Thousand CAD | -83.1% |
| 2009 Q2 | 182.54 Thousand CAD | -58.3% |
| 2009 Q3 | 35.66 Thousand CAD | -80.46% |
| 2009 Q1 | 437.79 Thousand CAD | 110.05% |
| 2008 Q4 | 208.42 Thousand CAD | -8.61% |
| 2008 Q3 | 228.06 Thousand CAD | 13.33% |
| 2008 FY | 1.07 Million CAD | 34.91% |
| 2008 Q2 | 201.24 Thousand CAD | -48.05% |
| 2008 Q1 | 387.39 Thousand CAD | 180.57% |
| 2007 Q2 | 127.03 Thousand CAD | 5.97% |
| 2007 FY | 797.18 Thousand CAD | 38.75% |
| 2007 Q4 | 138.07 Thousand CAD | -4.56% |
| 2007 Q3 | 144.67 Thousand CAD | 13.89% |
| 2007 Q1 | 119.87 Thousand CAD | -9.36% |
| 2006 FY | 574.53 Thousand CAD | -32.49% |
| 2006 Q4 | 132.24 Thousand CAD | -24.77% |
| 2006 Q3 | 175.79 Thousand CAD | 29.6% |
| 2006 Q2 | 135.64 Thousand CAD | 3.1% |
| 2006 Q1 | 131.56 Thousand CAD | -50.17% |
| 2005 Q2 | 287.5 Thousand CAD | -72.37% |
| 2005 Q1 | 1.04 Million CAD | 131.66% |
| 2005 FY | 850.97 Thousand CAD | -61.19% |
| 2005 Q4 | 264.01 Thousand CAD | 57.26% |
| 2005 Q3 | 167.88 Thousand CAD | -41.61% |
| 2004 FY | 2.19 Million CAD | 58.91% |
| 2004 Q1 | 1.19 Million CAD | 1121.31% |
| 2004 Q2 | 297.11 Thousand CAD | -75.06% |
| 2004 Q3 | 403.71 Thousand CAD | 35.88% |
| 2004 Q4 | 449.23 Thousand CAD | 11.28% |
| 2003 Q1 | 45.28 Thousand CAD | 162.9% |
| 2003 FY | 1.37 Million CAD | 516.35% |
| 2003 Q4 | 97.53 Thousand CAD | 525.4% |
| 2003 Q3 | 15.59 Thousand CAD | -79.39% |
| 2003 Q2 | 75.66 Thousand CAD | 67.07% |
| 2002 FY | 223.89 Thousand CAD | 13.53% |
| 2002 Q3 | 92.86 Thousand CAD | 35.55% |
| 2002 Q4 | 17.22 Thousand CAD | -81.45% |
| 2002 Q1 | 9073.00 CAD | -89.91% |
| 2002 Q2 | 68.5 Thousand CAD | 655.09% |
| 2001 Q4 | 89.95 Thousand CAD | 58.65% |
| 2001 Q3 | 56.7 Thousand CAD | 36.15% |
| 2001 Q2 | 41.64 Thousand CAD | -92.4% |
| 2001 Q1 | 547.68 Thousand CAD | 87.45% |
| 2001 FY | 197.2 Thousand CAD | -86.62% |
| 2000 Q2 | 255.15 Thousand CAD | -52.61% |
| 2000 FY | 1.47 Million CAD | 79.84% |
| 2000 Q1 | 538.38 Thousand CAD | 542.63% |
| 2000 Q4 | 292.18 Thousand CAD | -22.91% |
| 2000 Q3 | 378.99 Thousand CAD | 48.54% |
| 1999 Q4 | 83.77 Thousand CAD | -34.7% |
| 1999 FY | 819.61 Thousand CAD | 24.09% |
| 1999 Q1 | 405.41 Thousand CAD | 588.95% |
| 1999 Q2 | 69.15 Thousand CAD | -82.94% |
| 1999 Q3 | 128.29 Thousand CAD | 85.5% |
| 1998 FY | 660.51 Thousand CAD | -46.45% |
| 1998 Q4 | 58.84 Thousand CAD | -54.71% |
| 1998 Q2 | 138.84 Thousand CAD | 0.0% |
| 1998 Q3 | 129.91 Thousand CAD | -6.43% |
| 1997 FY | 1.23 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Covalon Technologies Ltd. | 14.36 Million CAD | 77.537% |
| Hemostemix Inc. | 2.15 Million CAD | -49.585% |
| Universal Ibogaine Inc. | 5.81 Million CAD | 44.539% |
| Kane Biotech Inc. | 3.46 Million CAD | 6.943% |
| MedMira Inc. | 1.5 Million CAD | -113.737% |
| Marvel Biosciences Corp. | 2.31 Million CAD | -39.123% |
| NervGen Pharma Corp. | 17.77 Million CAD | 81.852% |
| XORTX Therapeutics Inc. | 6.38 Million CAD | 49.448% |